Repurposing non-cancer drugs in oncology refers to the practice of identifying and investigating existing medications originally developed for other medical conditions to determine their potential efficacy in treating cancer. This approach offers several advantages, including shorter development timelines and reduced costs compared to developing entirely new cancer drugs.
Researchers explore a vast array of non-cancer drugs, such as anti-inflammatory, antiviral, or cardiovascular medications, searching for compounds that may inhibit cancer growth, metastasis, or provide supportive care for cancer patients. They are leveraging existing knowledge about these drugs’ safety profiles and mechanisms of action to accelerate their evaluation.
Repurposing non-cancer drugs can lead to groundbreaking discoveries, expanding treatment options for cancer patients. It also demonstrates the versatility of pharmaceutical compounds beyond their initial indications, potentially transforming the landscape of oncology therapeutics. This innovative approach holds promise for addressing the complexity and heterogeneity of cancer, ultimately improving patient outcomes.
Repurposed drugs are part of our treatment protocols and include:
• Acetylsalicylic Acid